NOT from insider buys, but RATHER that CRG is working harder than hell to steal the company from shareholders. In the end, I don't think Platinum will sit on their rumps and let this happen. They may even hire their own legal staff to protect their 10 million share position.
What an unimaginable and ridiculous situation the company has found itself in! What's next? The FDA declares that Lymphoseek can cure all cancers, HIV, and AIDS but the agency won't allow Lymphoseek to be used to treat them?
Navidea is the Alice in Wonderland Stock. What a rabbit hole.
#1) That Rick Gonzalez still gets a huge severance for all of his DISSERVICE to Navidea, even though this unfavorable CRG court ruling will make Navidea finances all the more limited. He deserves at least $1.5 million for his fine service to Navidea shareholders (I mean CRG and all other harmful entities of Navidea).
#2) That Brent Larson doesn't suffer one bit if the company can't afford to keep him on temporary disability as the unfavorable CRG rulings continue to come in. He worked hard for all shareholders and deserves a life of luxury forever with the 0.80 share price we are all so blessed with!
was sent by CRG to make further difficulty?
Probably not. Navidea is too trusting of all outside entities - perhaps because so few insiders own so few shares of the company (except for undeserved free shares of course).
It looks like it will take substantial time to conclude the case and all the while, Navidea stock and company reputation are getting damaged further and further...And we paid Pykett a $750K severance for his share of Navidea's woes? Ridiculous. The new CEO should be paid strictly on the basis of increased Lymphoseek sales and the advancement of MT. No severance should be in the new CEO contract whatsoever.
Lymphoseek sales going forward. If he can't get it done in Q2 and Q3 he should be terminated as well. All too often with Navidea, it seems as though they hire and retain the unwanted and unworthy, all the while, letting the company (and shareholders) settle for far less than mediocrity. ENOUGH!
I guess the Navidea shareholder can't have their cake and eat it too. Heck, we can't even have cake - all we get is s**t, quarter after quarter and year after year. I'm sure 2017 will be great. Lol.
Gonzalez was supposedly working on this. If the new CEO doesn't keep going with it, we won't get any Lymphoseek sales in 2016 or 2017 in the EU, but hey, what's another wasted year? Such has become standard with Navidea.
Very good. The situation the company presently finds itself in is all the more evidence that Larson never deserved any free shares and he has in fact, not done his job in an even minimal way.
I continue to be concerned with the direction, governance and control of the company as evidenced by the recent management, operational, financial and strategic issues being unilaterally decided by the executive committee without any input, discussion nor approval of the full board. I therefore find it impossible to discharge my duties as a board member and submit my resignation effective immediately. My best to the company.
I see that Good Old Gordon does not wish his best to shareholders. I'm not surprised. And if Troup (along with others) had "executed their duties" as EFFECTIVE board members, NAVB would never have been under 1.00. Good riddance to Troup and may Gonzalez and Larson SOON FOLLOW AND WITHOUT A CENT OF SEVERANCE!
Maybe the 4694 partnership is at hand. Or maybe a positive surprise is leaking out.
Either way, it's nice to see some more upward movement that is ABSOLUTELY OVERDUE!
it is better than .90-1.05. The news flow and updates will need to be constant and SUBSTANTIVE. Monday was full of teases and partial information. I fully expect each of the next two updates to contain more real information to drive shareholder value. Let us hope that RG will be dealt with once and for all and sooner than later. Let us hope that the 4694 deal is closed sooner than later AND that Navidea benefits from the deal. Let us hope that the Navidea shareholder will indeed benefit from the structure of MT, because anything less will be beyond unacceptable.
Even 1.75 is not celebratory territory for NAVB stock. We still have a long way to travel, but I am convinced that Goldberg is on the right track with his actions so far. How nice and helpful some Lymphoseek sales would be in Europe in 2016. Waiting until 2017 is unacceptable.
Compared to where the short position had an advantage with a pps of 1.00 vs. today's current pps of 1.43, they have lost $13.76 million of their gain. I don't believe that they could have covered 32,000,000 shares at 1.00, but 1.43 is far worse for them than 1.00. At an NAVB pps of 2.00, things could get real interesting as the TASE listing only required 15,000,000 shares of buying to move the pps up almost 1.00. A real short squeeze takes this stock back above 3.00.
Let's see if the company really has their ducks in a row for a change at 4:30.
Good question alex...I would phrase the question this way:
To Rick Gonzalez: WHERE THE FFFFFFFFFFFFFFFFFF IS THE UPDATE?
I drive a 2014 Honda Accord EX-L. The color is white orchid pearl (do a Google image search).
I was born in 1973. Use your head.
Aliens and Black Holes are sick and tired of blue dye! They need Lymphoseek NOW!
You may not laugh at my jokes - BUT I'M QUITE CERTAIN GONZALEZ AND LARSON ARE LAUGHING AT ALL OF US!
Platinum got NAVB listed on the TASE so that they could unload. I have an idea! Let's list NAVB on the planet Venus exchange to get the pps to 1.50, followed by Mars for 2.75, and then Jupiter for a 4.50 pps that would be out of this world! LOL.
The unfortunate reality is that moves like the TASE listing are all that can move NAVB - the company certainly remains committed to overcompensating themselves and ramming it to shareholders.
Is justice near?